Research and efficacy
There are many ongoing clinical trials to determine the effectiveness of facial rejuvenation using PRP and human biologics in randomized-controlled trials. The reported results involving small non-randomized studies to date have been mixed. There is no guarantee that this process will have the desired impact on your appearance. It is up to each patient to read and sign the informed consent prior to treatment. There are numerous published articles on these topics. Here is one that covers using PRP alone.
Read below for more understanding about our biologics, how they are harvested and how the specific products work to achieve the rejuvenation goal.
New Life Regenerative Medicine
We start using the best possible biologics to ensure safety, adherence to ethical harvesting, and provide the best chance for success. New Life regenerative products are donated from consenting mothers delivering by planned C-Sections. Following all AATB, FDA, and AABB requirements, New Life’s regenerative medicine products are safely cultivated and meet the highest quality assurance and ethical standards.
Understanding the Prescreening Process
Regenerative tissue is obtained from an expectant mother who consents to donate her birth tissues and agrees to a c-section delivery. The collection process is painless and poses absolutely no threat to the mother or her child. Donors are identified through participating OB doctors who have deemed the mothers’ pregnancies as normal and without complication. The mothers provide full consent and undergo comprehensive panel testing to determine eligibility as well as a thorough medical and social screening.
The mothers also undergo a physical exam. To be eligible to donate tissue, mothers must be free from any transmissible diseases, active malignancies, and sepsis or systemic infections. Donating mothers must also have no known high risk for HIV or Hepatitis.
Processing the tissues at the lab
At delivery, tissues are immediately and safely collected by trained technicians. They are transported overnight to the processing facility. In addition to the serological testing in the prescreening process, culturing is performed regularly during processing. All products are retested postprocessing to ensure the absence of bacterial and fungal pathogens.
During processing, a cryopreservative is introduced to the tissue to protect cell viability. Once packaged into vials, the products are sent to a third body testing facility to ensure sterility.
All products undergo a 14-day quarantine period. After 14 days, the product batches are randomly retested to demonstrate a continued absence of bacterial and fungal pathogens and are non-pyrogenic. A licensed medical director reviews all testing results before the products can be released for clinical use.